https://scholars.lib.ntu.edu.tw/handle/123456789/481855
標題: | Serum myostatin is reduced in individuals with metabolic syndrome | 作者: | DER-SHENG HAN Yu C.-S. CHIH-KANG CHIANG FEN-YU TSENG PING-HUEI TSENG CHI-LING CHEN KWAN-DUN WU WEI-SHIUNG YANG |
公開日期: | 2014 | 出版社: | Public Library of Science | 卷: | 9 | 期: | 9 | 起(迄)頁: | e108230 | 來源出版物: | PLoS ONE | 摘要: | Results: DM group had lower serum myostatin compared with non-diabetics (7.82 versus 9.28 ng/ml, p,0.01). Sixty-two percent of the recruited individuals had metabolic syndrome (MetS). The patients with MetS had significantly lower serum myostatin than those without (7.39 versus 9.49 ng/ml, p,0.001). The serum myostatin level decreased with increasing numbers of the MetS components (p for trend,0.001). The patients with higher body mass index, larger abdominal girth, lower high-density lipoprotein cholesterol (HDL-C), and higher triglycerides had lower serum myostatin than those without. The serum myostatin level was independently negatively related to larger abdominal girth, higher triglycerides, and lower HDL-C after adjustment. The odds ratios for MetS, central obesity, low HDL-C, high triglycerides, and DM were 0.85, 0.88, 0.89, 0.85, and 0.92, respectively, when serum myostatin increased per 1 ng/mL, in the binary logistic regression models.Conclusions: Lower serum myostatin independently associated with MetS, central obesity, low HDL-C, and high triglycerides after adjustment. Higher serum myostatin is associated with favorable metabolic profiles.Aims: Myostatin is a negative regulator of skeletal muscle mass and may also modulate energy metabolism secondarily. We aim to investigate the relationship between serum myostatin and the metabolic variables in diabetic (DM) and non-diabetic subjects.Materials and Methods: A cross-sectional study recruiting 246 consecutive DM patients and 82 age- and gender-matched non-diabetic individuals at a medical center was conducted. The variables of anthropometry and blood chemistry were obtained. Serum myostatin level was measured with enzyme immunoassay. ? 2014 Han et al. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84907452257&doi=10.1371%2fjournal.pone.0108230&partnerID=40&md5=5b6cd8af511d7708618c593132bd5707 https://scholars.lib.ntu.edu.tw/handle/123456789/481855 |
ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0108230 | SDG/關鍵字: | 2,4 thiazolidinedione derivative; alpha glucosidase inhibitor; antihypertensive agent; dipeptidyl peptidase IV inhibitor; fibric acid derivative; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; metformin; myostatin; oral antidiabetic agent; sulfonylurea; triacylglycerol; myostatin; adult; aged; anthropometry; Article; blood chemistry; blood sampling; body mass; controlled study; cross-sectional study; diabetes mellitus; enzyme immunoassay; female; human; major clinical study; male; metabolic syndrome X; obesity; protein blood level; blood; blood analysis; metabolic syndrome X; middle aged; risk factor; Adult; Aged; Blood Chemical Analysis; Cross-Sectional Studies; Female; Humans; Male; Metabolic Syndrome X; Middle Aged; Myostatin; Risk Factors |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。